Quentin Tannock (Exec. Chairman) and Dr Anna Duch (Senior Associate) prepared an IP Landscape snapshot of the personalised medicine area, presented in a paper at the OneNucleus Life Science Leadership Series in Cambridge, UK on 22nd May 2014.
This summary presentation introduces the diverse personalized medicine technology-market space which involves a range of processes, many pre-existing technologies and emerging innovations â€“ all of which can be the subject of patent applications. Patent activity trends in personalized medicine, including a noticeable spike in activity from around 2001 and information on key players is presented. Most important patented technologies and key geographical markets for personalized medicine innovations are identified. Drivers for patenting activity and for IP based partnerships are discussed, with case study examples presented including PrimeraDX/Eli Lilly, INSERM and Myraid Genetics. IP models from other industry areas are discussed and conclusions provided in relation to the importance of IP, Freedom to Operate and the impact on partnering of relative positioning of players in the personalized medicine industry value chain.